Mometasone Furoate Topical Solution 0.1% is used for hair loss, applied after showering and massaged into the damp scalp. The user is seeking information on its effectiveness for hair loss.
A user shared progress pictures after 4 months of using 1mg finasteride, a 0.25mm derma roller with rosemary oil, and biotin pills for hair loss. They reported being very happy with the results.
The conversation discusses using peppermint oil for hair loss, with one user applying it undiluted to the scalp and another combining it with finasteride and microneedling. Some believe in its effectiveness despite limited scientific evidence, and also mention rosemary oil as potentially beneficial.
Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.
Low-dose oral minoxidil is used for hair loss and does not significantly affect blood pressure but may increase heart rate and cause hypotensive symptoms. Some users experience side effects like palpitations and shortness of breath, while others find it effective; topical minoxidil with tretinoin is also considered.
The conversation discusses the effectiveness of peppermint oil and dermarolling for hair regrowth, with one person suggesting that only dermarolling is effective and comparing peppermint oil's effectiveness to that of an egg.
A 31-year-old man feels depressed due to hair loss, using topical finasteride and previously tried minoxidil. Others suggest treatments like finasteride, minoxidil, hair transplants, or embracing baldness, highlighting the importance of mental health and self-acceptance.
Creatine monohydrate's potential link to hair loss, with mixed opinions on its effects. Treatments like minoxidil, finasteride, and RU58841 are discussed.
Hair loss negatively affects mental health, causing anxiety and depression. Minoxidil and finasteride are discussed as treatments, but side effects and mental health concerns remain.
A satirical post jokes about a user meeting a doctor at the zoo who praises finasteride (Fin) for hair loss treatment, claiming it has a low side-effect profile and is effective. Replies include humorous disbelief, comparisons to other risks, and some personal accounts of side effects from Fin.
The conversation is about the prevalence of baldness among young men and the potential factors contributing to it. Specific treatments mentioned include minoxidil and finasteride.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
The conversation discusses whether to wait for Breezula while using topical minoxidil to avoid side effects from finasteride. It mentions Breezula's potential release in a year and its cost and long-term use considerations.
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
The conversation is about using bicalutamide, taken less frequently than daily, for hair loss treatment. The user is considering 50mg every 3 days or once a week and is asking for others' experiences.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.
Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.